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ABSTRACT 
 
Cyanobacteria, in particular those found living in the ocean, are emerging as an important 
source of unique bioactive secondary metabolites.  A plethora of natural products, mostly nitrogen-
containing molecules, have been reported with majority belonging to the polyketide synthase (PKS) 
and/or non-ribosomal polypeptide synthetase (NRPS) structural class.  Curacin A and the dolastatins 
are examples of important marine cyanobacterial metabolites possessing exquisite anticancer 
properties.  Genetic studies on the biosynthetic capacity of these marine microalgae revealed many 
novel biochemical features pertaining to the enzymology of secondary metabolism.  Biodiscovery of 
marine cyanobacteria for new therapeutic agents as well as harnessing its biosynthetic gene clusters 
represent an exciting and fruitful area of research in marine biotechnology. 
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INTRODUCTION 
 
Nature has been an important source of new 
pharmaceuticals in the treatment of various 
human diseases.  For instance about 60% 
and 75% of current drugs used in cancer and 
infectious diseases, respectively, derived 
from natural origin (Newman et al, 1997).  
Natural products research has traditionally 
been dominated by terrestrial organisms, 
such as plants and microbes.  This is not 
surprising due to the long history of human 
reliance on nature, especially plants for food 
and cures for human ailments.  However, the 
rate of discovery of novel compounds as 
potential drugs from terrestrial organisms in  
recent years is decreasing.  This is 
compounded by the urgent need for new 
therapeutics, especially antibiotics, driven 
largely by the emergence of multi-drug-
resistant pathogens.  Moreover, recent 
innovations such as combinatorial chemistry 
have met with limited success with regards to 
the development of new drugs. Therefore, it 
is critical that new sources of novel 
pharmaceuticals be uncovered and one of the 
solutions is natural products from marine 
organisms. 
The history of marine natural 
products started in the early 1950s and in 
spite of its short history, a number of notable 
biomolecules have been reported and they are 
currently in either preclinical or clinical 
testing(Newman and Cragg, 2004). These 
include ecteinascidin 743 (Yondelis™), 
bryostatin 1, and aplidine as potential 
anticancer drugs.  Some of these marine 
natural products are also potential lead 
compounds for synthesis of more potent 
analogs.  To date, more than 10,000 marine-
Review 
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derived compounds have been isolated and 
this is coming from less than 1% of the total 
marine biodiversity.  The range of marine 
organisms tapped for their natural products 
production includes sponges, tunicates, 
bryozoans, nudibranchs, and gorgonians.  Of 
these marine organisms, one particular 
group that is emerging as a source of 
important bioactive compounds is the 
marine blue-green algae or cyanobacteria 
(Gerwick et al, 2001). 
Considered to be an ancient group of 
microorganisms with fossil records dating 
back 3.5 billion years ago, these prokaryotic 
marine cyanobacteria are ubiquitous in 
nature and are found in wide ranging niches.  
Although they are microscopic, certain 
filamentous marine species are rather 
conspicuous occurring as extensive mats 
along tropical coastal areas.  Some 
unicellular species can also be found living 
in symbiotic relationships with other marine 
invertebrates such as tunicates and sponges.  
It is well documented that certain strains e.g. 
Lyngbya majuscula and Microcystis 
aeruginosa, produced cyanotoxins that have 
implications in human health.  These include 
the dermatoxin, lyngbyatoxin A and the 
hepatotoxins, microcystins and nodularins 
(Carmichael, 1992).  In addition of these 
cyanotoxins, a wide range of useful 
secondary metabolites have also been 
reported and this review highlights the 
chemistry, biology as well as the 
biosyntheses of some of these unique marine 
cyanobacterial natural products. 
 
 
 
MARINE CYANOBACTERIAL 
NATURAL PRODUCTS  
 
Two main research groups, Professor Richard 
Moore’s research group at the University of 
Hawaii and Professor William Gerwick’s 
research group at University of California at 
San Diego, contributed significantly to the 
knowledge of natural products chemistry of 
marine cyanobacteria (  Gerwick et al, 2001; 
Moore, 1996).  Majority of their 
cyanobacterial collections centered on reef 
systems in Hawaii, Guam, the Caribbean, 
Madagascar, and Papua New Guinea.  From 
their extensive studies, it has been shown that 
cyanobacterial species, especially those 
belonging to the benthic genus Lyngbya are a 
prolific source of unique bioactive natural 
molecules (Gerwicket al, 2001). The 
circumtropical Lyngbya species are 
widespread in distribution and are considered 
to be one of the most abundant filamentous 
marine cyanobacteria.  For instance, one 
particular species, L. majuscula, yielded over 
30% of all marine cyanobacterial metabolites, 
reflecting its impressive biosynthetic capacity 
with regards to natural products production.  
Certain strains of L. majuscula are also 
deemed as “super” producer of secondary 
metabolites, represented by different 
structural classes (Gerwick et al, 2001). An 
example is L. majuscula strain 19L (Figure 1) 
collected from the Curaçao where at least six 
compounds, curacin A (antimitotic), 
barbamide (molluscicidal), malyngamide H 
(brine shrimp toxic), antillatoxin (neurotoxin 
and ichthyotoxic), carmabins A and B, have 
been reported, each with unique biological 
properties.
 
 
Figure 1.  Lyngbya majuscula (19L) 
(Picture provided by Dr. William Gerwick) 
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Currently, there are well over 200 
secondary metabolites, mostly nitrogen-
containing molecules, being reported from 
marine cyanobacteria.  These natural 
products represent great structural diversity, 
belonging to the polyketide synthase (PKS), 
non-ribosomal polypeptide synthetase 
(NRPS), as well as hybrid PKS-NRPS 
structural classes(Gerwick et al, 2001). 
Certain signature structural motifs can also 
be observed amongst these diverse 
cyanobacterial molecules.  There is a high 
preponderance of compounds containing 
amino or hydroxy acids (e.g. the 
wewakpeptins in Figure 3), pyrrolidone 
rings (e.g. jamaicamide A in Figure 3) and 
heterocyclic moieties such as thiazoline, 
thiazole, oxazoline, and oxazole flanked by 
amino or hydroxy acids (e.g. dolastatin 10 in 
Figure 2).  In addition, majority of the PKS-
derived  amino or  hydroxy acid moieties are 
found in cyclic peptides and they possess a 
methyl (e.g. hectochlorin in Figure 3) or 
dimethyl group (e.g. lyngbyabellin A and 
wewakpeptins in Figure 3) at the C position.   
A number of important marine 
cyanobacterial molecules, including 
dolastatin 10, cryptophycins and curacin A, 
have been discovered and these were either 
in preclinical or clinical testing as anticancer 
agents (Newman and Cragg, 2004).  Marine 
cyanobacterial molecules with potent 
biological activities are also lead compounds 
for the development of synthetic analogs 
having increased potency and decreased 
toxicity (Figure 2).  For instance, the potent 
antimitotic agent, curacin A (Figure 2), was 
initially isolated from a field collection of the 
marine cyanobacterium, Lyngbya majuscula, 
obtained from Curaçao (Gerwick et al, 1994). 
Since its discovery curacin A has served as a 
lead compound for the development of 
synthetic analogs which are more soluble 
(Wipf et al, 2004). Another important class of 
molecules is the dolastatins which were 
initially isolated from the sea hare Dolabella 
auricularia.  However, recent studies have 
revealed the dietary origin of these potent 
molecules from marine cyanobacteria.  Two 
synthetic analogs, cematodin (a water soluble 
analog of dolastatin 15) and TZT-1027 
(dolastatin 10 analog) are currently being 
evaluated in phase II clinical trials as 
potential drugs for treatment of advanced 
solid tumors (Figure 2) (Newman and Cragg, 
2004). 
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Figure 2.  Marine cyanobacterial metabolites as lead compounds. 
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Recent literature on natural products 
from marine cyanobacteria indicated that 
these microorganisms continue to be 
impressive with reports of novel chemical 
structures along with useful biological 
properties.  Despite wide ranging biological 
activities reported for these compounds, 
several main pharmacological trends are 
emerging.  Some marine cyanobacterial 
molecules are found to target either the 
polymerization of actin (e.g. hectochlorin) 
or tubulin (e.g. curacin A and dolastatin 10).  
In addition, a number of neurotoxins act as 
either blockers (e.g. jamaicamides and 
kalkitoxin) or activators (antillatoxin) of the 
mammalian voltage-gated sodium channel 
(Figure 3) (Gerwick et al, 2001). 
A recent example of a potent 
promoter of actin assembly is hectochlorin, 
originally isolated from Lyngbya majuscula 
procured from Hector Bay, Jamaica and 
Boca del Drago Beach, Panama (Figure 3) 
(Marquez et al, 2002). Structurally it is very 
similar to another group of marine 
cyanobacterial compounds the 
lyngbyabellins (Figure 3) and dolabellin, a 
seahare-derived molecule.  The unique 
feature of this molecule is that the molecule 
is composed of carbonyl ester linkages 
unlike most other compounds which consist 
of a mixture of carbonyl amide and carbonyl 
ester bonds.  Hectochlorin was tested in the 
National Cancer Institute and found to have 
pronounced antiproliferative activities against 
colon, melanoma, ovarian, and renal panels 
with an average GI50 against the 60 cell lines 
of 5.1 M.  In addition, hectochlorin possess 
significant antifungal activity against 
Candida albicans (Marquez et al, 2002). 
The lipopeptide, kalkitoxin is a 
potent neurotoxin initially isolated from 
Lyngbya majuscula from the Caribbean (Wu 
et al, 2000). The neurotoxic nature of this 
important molecule was first detected from 
fish toxicity assay.  Since its discovery, a 
number of research groups have successfully 
reported its total synthesis.  Preliminary 
research revealed that this molecule is more 
potent than saxitoxin in blocking the voltage 
sensitive Na+ channel in mouse neuro-2a cells 
with EC50 of 1 nM,.  Due to availability of 
synthetic material, kalkitoxin was further 
evaluated for its interaction with voltage-
sensitive sodium channels in cerebellar 
granule neurons (CGN) and was found to 
have significant antagonistic effect on 
veratridine-induced cytotoxicity and Ca2+ 
influx in CGN.  These series of biological 
data on kalkitoxin suggest the importance of 
this molecule as possible lead compound for 
the development of analgesic as well as 
neuroprotection drugs (LePage et al, 2005). 
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Figure 3.  Selected examples of bioactive marine cyanobacterial molecules. 
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Other noteworthy marine 
cyanobacterial molecules reported recently 
in the literature having significant biological 
activities include the apratoxins (Luesch et 
al, 2001) (cytotoxic agents), the 
lyngbyabellins (Milligan et al, 2000) 
(cytotoxic and antifungal), and the 
wewakpeptins (Han et al, 2005) (Figure 3).  
Some of these molecules possess exquisite 
biological properties usually in the low 
micromolar or nanomolar range.  For 
instance, apratoxin A, first isolated from 
Lyngbya majuscula found at Apra Harbor, 
Guam, is a potent cytotoxin with a unique 
carbon skeleton.  It possesses an impressive 
biological profile in in vitro cytotoxicity 
against various human tumor cell lines with 
IC50 ranging from 0.36 to 0.52 nM.  Its 
complete structure elucidation involved 
extensive NMR spectroscopy experiments as 
well as chemical manipulations.  Total 
synthesis of apratoxin A has been 
accomplished leading the way to synthetic 
analogs for the purpose of new therapeutics 
(Chen and Forsyth, 2004). 
BIOSYNTHESIS OF MARINE 
CYANOBACTERIAL NATURAL 
PRODUCTS  
 
As evident from above examples, most of 
these marine cyanobacterial molecules are 
biosynthesized by large multi-modular 
enzymatic systems coded by polyketide 
synthase (PKS)-non-ribosomal polypeptide 
synthetase (NRPS) gene clusters.  To date 
only three putative biosynthetic PKS-NRPS 
gene clusters of marine cyanobacterial 
molecules have been reported including 
barbamide, curacin A, and jamaicamides 
(Chang et al, 2002, 2004; Edwards et al, 
2004). Despite just three examples, its genetic 
studies revealed high novelty and complexity 
of the gene clusters.  The first complete 
biosynthetic gene cluster reported was 
barbamide, a molluscicidal compound 
containing a unique trichloroleucine unit 
(Figure 4) (Chang et al, 2002). 
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Figure 4.  Biosynthetic studies and the involvement of bar gene clusters in the assembly of 
barbamide. 
 
The putative identification of bar gene 
cluster was aided by extensive biosynthetic 
feeding experiments which suggested a 
mixed PKS-NRPS assembly of the molecule 
(Figure 4).  A number of notable 
biosynthetic features include biochemical  
 
mechanisms for chlorination of the starter 
unit, leucine, the formation of thiazole moiety 
through oxidative decarboxylation, and the 
formation of E-double bond in barbamide 
(Figure 4) (Chang et al, 2002). Genetic 
studies on other molecules such as curacin     
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a and the jamaicamides have also revealed 
high degree of biochemical novelty and 
some of these features are summarized in 
Table 1.
 
Table 1.  Notable biochemical features of the biosynthetic gene clusters of marine 
cyanobacterial molecules. 
 
Marine Cyanobacterial 
Molecules 
Gene 
Size 
Notable Biochemical Features 
Barbamide 
(Figure 4) 
26 kb 1.  Unique chlorination of leucine 
2.  E-double bond formation between C4-C5 
3.  Carbon truncation during chain elongation 
4.  Thiazole ring formation 
Curacin A 
(Figure 2) 
64 kb 1.  Involvement of HMG-CoA in formation of cyclopropyl ring 
2.  Unique chain termination involving product release and 
terminal dehydrative decarboxylation yielding a methylene 
group 
Jamaicamides 
(Figure 3) 
58 kb 1.  Tight integration of mixed PKS/NRPS pathway 
2.  Involvement of HMG-CoA in formation of vinyl/vinyl 
chloride group 
3.  Incorporation of unique alkynyl starter unit 
4.  Unique chain termination yielding pyrrolinone ring   
 
One interesting aspects of the 
biosynthetic gene clusters identified from 
marine cyanobacteria is the absence of self-
resistance, regulatory, or transport genes. 
These are usually found in biosynthetic gene 
clusters of actinomycetes (Edwards et al, 
2004). In addition to the mixed PKS-NRPS 
structural types, recent chemical studies 
have shown that marine cyanobacteria are 
capable of producing a wide range of other 
non PKS-NRPS molecules. This is indicated 
by the recent report of swinholide A, a 
macrolide, from Symploca cf. sp. and 
Geitlerinema sp. collected from the Fiji 
Islands and Nosy Mitso-ankaraha Island, 
Madagascar, respectively (Andrianasolo et 
al, 2005). 
 
CONCLUDING REMARKS 
 
Marine cyanobacteria would probably 
ranked along side the actinomycetes and 
myxobacteria as a prolific producer of 
unique natural products.  Natural products 
research on these ancient microorganisms is 
still in its infancy despite the seemingly 
numerous publications on its chemistry.  
Majority of the research papers is dominated 
by cyanobacterial collections from reef 
systems in Hawaii, the Caribbean, 
Madagascar, and Papua New Guinea.   
However, nothing is known on the chemistry 
of marine cyanobacteria from other parts of 
the world, such as South East Asia where 
biodiversity is high.  For instance, 
preliminary field surveys at just two southern 
islands, St. John’s Island and Pulau Hantu in 
Singapore, indicated presence of abundant 
Lyngbya species (author’s unpublished data).  
Field collections of these microorganisms 
were initiated and their organic extracts 
indicated significant biological activity based 
on brine shrimp (Artemia salina) lethality 
assay (author’s unpublished data).  Thus it is 
believed that many more unique marine 
cyanobacterial biomolecules will be 
uncovered from other geographically 
unexplored areas. 
Results from marine cyanobacterial 
biosynthetic gene clusters studies provided 
important insights to understanding the 
molecular mechanisms of secondary 
metabolism in these microorganisms.  A 
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number of biochemical novelties have been 
revealed, including genes coding for unique 
tailoring enzymes for the final production of 
natural products.  Identification of putative 
modular gene cluster systems set the stage 
for future work in combinatorial 
biosynthesis in producing “unnatural” 
natural products through modular swapping 
as well as heterologous expression of 
important cyanobacterial biomolecules using 
Escherichia coli or Streptomyces lividens 
model.  The latter approach would be useful 
especially from marine cyanobacterial 
strains that are difficult to culture or slow 
growing.  In conclusion natural products 
research coupled with genetic studies on the 
biosynthesis of unique metabolites in marine 
cyanobacteria represent an exciting and 
fruitful enterprise in the area of marine 
biotechnology. 
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